×
Back to Agenda
Risk Management in Advanced Device Technology Development
Session Chair(s)
James Wabby, MHS
VP, Head of Regulatory Strategy, Emerging Technologies and Combination Products, AbbVie, United States
This panel will discuss innovative medical products due to their contribution to advancing medical care and are thus expected to have major impact in the coming years. Risk management pertaining to future technologies will be critical as product become more patient centric.
Learning Objective : Analyze latest expectations and challenges utilizing an integrated risk management approach for combination products; Discuss the importance of an integrated risk management approach to increase product understanding earlier within the product development phase.
Speaker(s)
Kimberly Trautman, MS
Managing Director, Trautman International Services, United States
Panelist
Donna Rycroft, BSN
Director, Study Risk Management, AbbVie, United States
Panelist
Olivia Wong, MBA
Director, Quality, Combination Products, Gilead, United States
Panelist
Have an account?